Explore the words cloud of the PnuBioVax project. It provides you a very rough idea of what is the project "PnuBioVax" about.
The following table provides information about the project.
Coordinator |
IMMUNOBIOLOGY LIMITED
Organization address contact info |
Coordinator Country | United Kingdom [UK] |
Project website | http://www.immbio.net/ |
Total cost | 71˙429 € |
EC max contribution | 50˙000 € (70%) |
Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
Code Call | H2020-SMEInst-2018-2020-1 |
Funding Scheme | SME-1 |
Starting year | 2019 |
Duration (year-month-day) | from 2019-05-01 to 2019-09-30 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | IMMUNOBIOLOGY LIMITED | UK (CAMBRIDGE) | coordinator | 50˙000.00 |
Pneumococcal disease, caused by the pathogenic bacteria Streptococcus pneumoniae, is a major cause of mortality in the young and elderly. In Europe, it is responsible for 230,000 annual deaths and an economic burden of € 10B annually. Due to the high cost of the current vaccines, rates of infant disease and death are even higher in developing countries, accounting for 1.6M deaths per year. The introduction of pneumococcal vaccines in Europe over the 20th century was pivotal in the reduction of pneumococcal pneumonia cases by 31%. Despite these good results, vaccine efficiency is now decreasing due to the adaptation of S. pneumoniae to the existing vaccines, but also due to its growing antibiotic resistance.
ImmunoBiology’s (ImmBio) platform technology has been used to create a pneumococcal vaccine called PnuBioVax™ (PBV) that aims to address the burden of the disease by offering protection against 100% of the pneumococcal strains. As a result of low manufacturing costs (<€ 1), PBV could become a game changer in the combat of the disease, facilitating its adoption in developing countries. The manufacturing cost of PBV represents a reduction of >95% compared to PCV13, the market leader, estimated at € 20. The vaccine has already been tested in humans, demonstrating its safety and effectiveness.
ImmBio is an innovative company, established in 1999 in the UK, which develops state-of-the-art vaccines using the ImmBioVax™ (IBV) vaccine platform technology. To date, ImmBio has raised circa € 10M in grants and awards. These funds, allowed the company to take the IBV technology from concept to clinical readiness products. The proposed work in Phase 1 of the SME instrument fits into their overall plan to reach the market by contributing to the financial resources needed to complete PBV’ clinical studies and ensure market uptake.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PNUBIOVAX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "PNUBIOVAX" are provided by the European Opendata Portal: CORDIS opendata.
INSIGHTS FOR TALENT ASSESSMENT USING COMPUTER VISION TECHNIQUES FROM NEURO PSYCHOLOGY
Read MoreTracworx is a data analytics tool that allows you to establish bottlenecks in your patient flow, while understanding your efficiencies and ultimately your true capacity.
Read More